Literature DB >> 34364544

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.

Mohammed Eslam1, Naim Alkhouri2, Pietro Vajro3, Ulrich Baumann4, Ram Weiss5, Piotr Socha6, Claude Marcus7, Way Seah Lee8, Deirdre Kelly9, Gilda Porta10, Mohamed A El-Guindi11, Anna Alisi12, Jake P Mann13, Nezha Mouane14, Louise A Baur15, Anil Dhawan16, Jacob George17.   

Abstract

The term non-alcoholic fatty liver disease (NAFLD), and its definition, have limitations for both adults and children. The definition is most problematic for children, for whom alcohol consumption is usually not a concern. This problematic definition has prompted a consensus to rename and redefine adult NAFLD associated with metabolic dysregulation to metabolic (dysfunction)-associated fatty liver disease (MAFLD). Similarities, distinctions, and differences exist in the causes, natural history, and prognosis of fatty liver diseases in children compared with adults. In this Viewpoint we, an international panel, propose an overarching framework for paediatric fatty liver diseases and an age-appropriate MAFLD definition based on sex and age percentiles. The framework recognises the possibility of other coexisting systemic fatty liver diseases in children. The new MAFLD diagnostic criteria provide paediatricians with a conceptual scaffold for disease diagnosis, risk stratification, and improved clinical and multidisciplinary care, and they align with a definition that is valid across the lifespan.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 34364544     DOI: 10.1016/S2468-1253(21)00183-7

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  26 in total

1.  Dietary sugar restriction reduces hepatic de novo lipogenesis in boys with fatty liver disease.

Authors:  Stephanie T Chung; Sheela N Magge
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

Review 2.  Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Authors:  Shreya C Pal; Mohammed Eslam; Nahum Mendez-Sanchez
Journal:  Hormones (Athens)       Date:  2022-08-03       Impact factor: 3.419

Review 3.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

4.  Evaluating 12 Years of Implementing a Multidisciplinary Specialist Child and Adolescent Obesity Treatment Service: Patient-Level Outcomes.

Authors:  Cathy Wyse; Lucinda Case; Órla Walsh; Catherine Shortall; Norah Jordan; Lois McCrea; Grace O'Malley
Journal:  Front Nutr       Date:  2022-06-03

Review 5.  The Role of Phytosterols in Nonalcoholic Fatty Liver Disease.

Authors:  Otilia Frasinariu; Roxana Serban; Laura Mihaela Trandafir; Ingrith Miron; Magdalena Starcea; Ioana Vasiliu; Anna Alisi; Oana Raluca Temneanu
Journal:  Nutrients       Date:  2022-05-24       Impact factor: 6.706

6.  Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats.

Authors:  Guoying Zhu; Li Chen; Su Liu; Ling She; Yongnian Ding; Changqing Yang; Fengshang Zhu
Journal:  Heliyon       Date:  2022-07-05

7.  A Proposal to Unify the Definition of the Metabolic Syndrome in Children and Adolescents.

Authors:  Xin'nan Zong; Pascal Bovet; Bo Xi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

Review 8.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

9.  Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study.

Authors:  Xiaofen Xie; Bing Guo; Ting Chen; Baima Kangzhuo; Xing Zhao; Xiong Xiao; Jianzhong Yin; Ziyun Wang; Xiaoman Jiang; Jingzhong Li; Lu Long; Junmin Zhou; Ning Zhang; Yuan Zhang
Journal:  BMC Public Health       Date:  2022-01-17       Impact factor: 3.295

Review 10.  Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update.

Authors:  Jawaher Alharthi; Mohammed Eslam
Journal:  J Clin Transl Hepatol       Date:  2021-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.